Natco Pharma Ltd. has approved the incorporation of a wholly-owned subsidiary to facilitate the demerger of its Crop Health Sciences division. Additionally, the company has declared a second interim dividend of ₹1.50 per equity share for FY 2025-26, with the record date set for November 20, 2025.
NATCOPHARM) has announced two key developments as per its latest regulatory filing with the National Stock Exchange (NSE). The company’s board has approved the formation of a new wholly-owned subsidiary in India, which will serve as the resulting company for the proposed demerger of its Crop Health Sciences division. This move is aimed at unlocking value and enabling focused growth in the agro-chemical segment.
In a parallel announcement, Natco Pharma has declared a second interim dividend of ₹1.50 per equity share (75 percent of the face value of ₹2) for the financial year 2025-26.
Important points:
- Demerger to be executed through a scheme of arrangement under Sections 230 to 232 of the Companies Act, 2013
- The new subsidiary will be incorporated in India and will house the Crop Health Sciences business post-demerger
- Interim dividend declared at ₹1.50 per share; record date is November 20, 2025
- Dividend payment scheduled to commence from November 28, 2025
Source: NSE Circular dated November 14, 2025 (NATCO PHARMA LIMITED - Symbol: NATCOPHARM)